Distinguishing early-stage pancreatic cancer patients from disease-free individuals using serum profiling.
This study evaluated the usefulness of electrospray mass spectrometry to distinguish sera of early-stage pancreatic cancer patients from disease-free individuals. Sera peak data were generated from 33 pancreatic cancer patients and 30 disease-free individuals. A "leave one out" cross-validation procedure discriminated stage I/II pancreatic cancer versus disease-free sera with a p value <.001 and a receiver-operator characteristic curve area value of 0.85. Predictive values for cancer stage I/II test efficiency, specificity, and sensitivity were 78%, 77%, and 79%, respectively. These studies indicate that electrospray mass spectrometry is useful for distinguishing sera of early-stage pancreatic cancer patients from disease-free individuals.
Department of Biochemistry & Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104, USA.
James R
JR
Hocker
Megan R
MR
Lerner
Stephanie L
SL
Mitchell
Stan A
SA
Lightfoot
Theresa J
TJ
Lander
Aurelien A
AA
Quillet
Rushie J
RJ
Hanas
Marvin D
MD
Peyton
Russell G
RG
Postier
Daniel J
DJ
Brackett
Jay S
JS
Hanas
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D055088:Early Detection of Cancer / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D011237:Predictive Value of Tests; D021241:Spectrometry, Mass, Electrospray Ionization